000			02975cam a2200349 a 4500
003			EG-GiCUC
005			20250223032453.0
008			191205s2019 ua f m 000 0 eng d
040			_aEG-GiCUC _beng _cEG-GiCUC
041	0		_aeng
049			_aDeposite
097			_aM.Sc
099			_aCai01.19.04.M.Sc.2019.Ma.P
100	0		_aManar Saad Mohamed Ramadan
245	1	0	_aPrognostic factors in metastatic renal cell carcinoma patients in relation to targeted therapy / _cManar Saad Mohamed Ramadan ; Supervised Hanan Ezzat Shafik , Ahmed Abdelraheem Alnagar , Nevine Fayez Habashy
246	1	5	_aالسمات التنبوئية للمرضى المصابين بسرطان الخلايا الكلوية المنتشر و المتعلقة بالعلاج الموجه
260			_aCairo : _bManar Saad Mohamed Ramadan , _c2019
300			_a97 P. ; _c25cm
502			_aThesis (M.Sc.) - Cairo University - National Cancer Institute - Department of Oncology-Medical
520			_aKidney cancer accounts for 5% and 3% of all adult malignancies in men and women, respectively with renal cell carcinoma (RCC) accounts for {u223C} 80% of all kidney cancers. Several agents targeting the vascular endothelial growth factor (VEGF) pathway or the mammalian target of rapamycin (mTOR) pathway were progressively approved for first-line or later-line use in the treatment of patients with advanced RCC and became the new standard of care. The aim of the study is to clarify the clinical and pathological features of metastatic renal cell carcinoma (RCC) cases and correlate the use of targeted therapy with the outcome and survival. Our study included 73 patients diagnosed and managed at medical oncology department of National cancer institute (NCI), Cairo university and Zagazig University Hospitals with 59 patients received targeted therapy after radical nephrectomy and 14 patients had only radical nephrectomy. The study was approved by the institutional review board (IRB), of NCI, Egypt. The overall response rate (RR) was 39% with the median follow up duration was 22.4 months (Range 1.13-64.2) while the overall disease control rate (DCR) was 79.7%. Median overall survival was 32.6 months while median progression free survival (PFS) was 12.7 months. Patients who received targeted therapy had a significant impact on OS, PFS and RR with sunitinib showed better survival than pazopanib as first line, but didn{u2019}t affect the response. The IMDC prognostic model had a better significant relation with the response and survival than MSKCC model
530			_aIssued also as CD
653		4	_aMetastatic renal cell carcinoma
653		4	_aPazopanib
653		4	_aSunitinib
700	0		_aAhmed Abdelraheem Alnagar , _eSupervisor
700	0		_aHanan Ezzat Shafik , _eSupervisor
700	0		_aNevine Fayez Habashy , _eSupervisor
856			_uhttp://172.23.153.220/th.pdf
905			_aNazla _eRevisor
905			_aSamia _eCataloger
942			_2ddc _cTH
999			_c75645 _d75645